Similar articles

• Iloprost in peripheral vascular disease--platelet function and clinical outcome.

  Fitscha P, Tiso B, Sinzinger H. Fitscha P, et al. Prog Clin Biol Res. 1987;242:463-8. Prog Clin Biol Res. 1987. PMID: 2444993 Clinical Trial. No abstract available.
• Effect of iloprost on in vivo and in vitro platelet function in patients with peripheral vascular disease (PVD).

  Fitscha P, Tiso B, Krais T, Sinzinger H. Fitscha P, et al. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:450-4. Adv Prostaglandin Thromboxane Leukot Res. 1987. PMID: 2444079 Clinical Trial. No abstract available.
• Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.

  Sinzinger H, Virgolini I, O'Grady J. Sinzinger H, et al. Prog Clin Biol Res. 1989;301:85-96. Prog Clin Biol Res. 1989. PMID: 2477859 Review. No abstract available.
• Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease.

  Müller B, Krais T, Stürzebecher S, Witt W, Schillinger E, Baldus B. Müller B, et al. Biomed Biochim Acta. 1988;47(10-11):S40-4. Biomed Biochim Acta. 1988. PMID: 2470358 Clinical Trial.
• Prostacyclin in vascular pathology--therapeutic possibilities.

  Gryglewski RJ, Szczeklik A. Gryglewski RJ, et al. Ann Clin Res. 1984;16(5-6):253-61. Ann Clin Res. 1984. PMID: 6398663 Review. No abstract available.